


# Recombinant Vaccines Market to Reach USD 32.83 Billion by 2032, Growing at 11.88% CAGR

*Driven by advancements in biotechnology and rising demand for immunization, the recombinant vaccines market is set for significant expansion through 2032.*

AUSTIN, TX, UNITED STATES, February 28, 2025 /EINPresswire.com/ -- According to Research by SNS Insider, The [Recombinant Vaccines Market](#) was estimated at USD 12.53 billion in 2023 and is expected to reach USD 32.83 billion by 2032, at a CAGR of 11.88% during the forecast period of 2024-2032.



Recombinant Vaccines Market

The Recombinant Vaccines Market is growing fast, supported by developments in biotechnology, increased demand for effective and safer vaccines, and higher immunization programs globally. The use of genetically modified vaccines for conditions such as HPV, hepatitis B, and COVID-19 is growing. Moreover, government support, R&D activities, and technological advancements are driving market growth faster. The transition to recombinant platforms for quicker vaccine development also supports continued market expansion.

Get a Free Sample Report@ <https://www.snsinsider.com/sample-request/3239>

## Key Players in Recombinant Vaccines Market

- GlaxoSmithKline plc.
- C.H. Boehringer Sohn AG & Co.KG
- Merck & Co. Inc
- Sanofi
- Pfizer Inc.
- LG Chem
- Dynavax Technologies
- Serum Institute of India Pvt. Ltd

- Novartis AG
- Sinovac Biotech Ltd

## Segmentation Insights

By Type, the subunit vaccines segment dominated the 2023 Recombinant Vaccines Market with a 75% market share in 2023.

The dominance of the segment is because it has a very high safety record, robust immunogenicity response, and universal use within immunization regimens. Compared to live or inactivated vaccines, subunit vaccines have no unnecessary antigens, lowering adverse reactions and also making them possible to use within immunocompromised patients. Their ability to cause disease avoidance, such as from hepatitis B, HPV, and pertussis, has increased demand. Moreover, innovations in recombinant DNA technology have made it possible to produce very targeted and scalable vaccine formulations. More government spending and support on vaccination schemes further bolstered the dominance of the segment. Ongoing R&D activities aimed at improving the effectiveness of subunit vaccines and improving production efficiency are further cementing its position of leadership in the market.

By Route of Administration, the parenteral segment dominated the Recombinant Vaccines Market with the highest share in 2023

The parental segment dominated because of its established efficacy, universal acceptance, and conventional delivery route. Intramuscular or subcutaneous injections are used to deliver most recombinant vaccines, such as HPV, hepatitis B, and COVID-19 vaccines, allowing for accurate dosing and robust immune responses. Parenteral vaccines offer fast antigen presentation, resulting in higher immunogenicity than oral delivery. Moreover, regulatory clearances and standing infrastructure for injectable vaccines are among the factors that make this segment all-dominant. Immunization campaigns by governments, the preferences of healthcare providers, and mass vaccination efforts also favor this segment. Although developments in oral vaccine technologies have improved, the parenteral route is the norm for most recombinant vaccines, making it the market leader. Nevertheless, research on oral options continues to advance incrementally.

By Indication, the HPV segment dominated the recombinant vaccines market with a 25% market share in 2023.

HPV segment is owing to the high worldwide prevalence of human papillomavirus (HPV) infection and its established linkage with cervical cancer and other cancers. High-priority vaccines such as Gardasil and Cervarix have found large-scale inclusion in national immunization programs, leading to substantial demand in the market. Government-supported HPV vaccination campaigns, especially in the age group of adolescents and young adults, further propelled acceptance. Besides, rising awareness of HPV cancers and mounting suggestions by health

agencies like the WHO and CDC have boosted growth. The rising emphasis on preventive care and broader vaccine penetration in emerging economies have consolidated the leadership of this segment. Constant R&D activity towards next-generation HPV vaccines keeps supporting market growth and maintaining the leadership of this segment.

Speak with Our Expert Analyst Today to Gain Deeper Insights @  
<https://www.snsinsider.com/request-analyst/3239>

North America dominated the recombinant vaccines market with a 39% market share in 2023.

The region's dominance is due to its advanced biotechnology base, sophisticated healthcare infrastructure, and high rates of immunization. The region hosts top vaccine-producing companies such as Merck & Co., Pfizer, and Sanofi, contributing to ongoing innovations. Strong government support, grants for vaccine development, and the common use of recombinant technology also drive the market growth. The U.S. and Canada's established reimbursement policies and regulatory framework further assist in the acceptance of recombinant vaccines, making the region the leader.

Asia-Pacific is the fastest-growing region in the market with the highest CAGR throughout the forecast period, spurred by growth in population, rising disease burden, and growth in vaccination programs. China, India, and Japan are investing significantly in local vaccine production and biopharmaceutical research. Moreover, government-supported immunization programs and advancing healthcare infrastructure also fuel growth. Increasing demand for affordable recombinant vaccines comes as a result of growing middle-class populations and growing healthcare expenditures. Collaboration among global and regional vaccine manufacturers further propels market growth in the Asia-Pacific.

Buy Full Research Report on Recombinant Vaccines Market 2024-2032 @  
<https://www.snsinsider.com/checkout/3239>

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Jagney Dave  
SNS Insider Pvt. Ltd  
+1 315 636 4242

[email us here](#)

Visit us on social media:

Facebook  
X  
LinkedIn  
Instagram

---

This press release can be viewed online at: <https://www.einpresswire.com/article/790053781>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.